<?xml version='1.0' encoding='utf-8'?>
<document id="31330787"><sentence text="Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats."><entity charOffset="10-20" id="DDI-PubMed.31330787.s1.e0" text="Ticagrelor" /><entity charOffset="82-91" id="DDI-PubMed.31330787.s1.e1" text="Tadalafil" /><pair ddi="false" e1="DDI-PubMed.31330787.s1.e0" e2="DDI-PubMed.31330787.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31330787.s1.e0" e2="DDI-PubMed.31330787.s1.e1" /></sentence><sentence text="Tadalafil is a cytochrome P450 (CYP) 3A4 substrate"><entity charOffset="0-9" id="DDI-PubMed.31330787.s2.e0" text="Tadalafil" /></sentence><sentence text=" Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors"><entity charOffset="126-135" id="DDI-PubMed.31330787.s3.e0" text="tadalafil" /></sentence><sentence text=" This study was conducted to assess the effect of ticagrelor, a CYP3A4 inhibitor, on the pharmacokinetic properties of tadalafil after oral administration to rats"><entity charOffset="119-128" id="DDI-PubMed.31330787.s4.e0" text="tadalafil" /></sentence><sentence text=" A total of 20 Sprague-Dawley male rats were randomly divided into the non-pretreated group and ticagrelor-pretreated group, and tadalafil was orally administered to each group after pretreatment with or without ticagrelor"><entity charOffset="96-106" id="DDI-PubMed.31330787.s5.e0" text="ticagrelor" /><entity charOffset="129-138" id="DDI-PubMed.31330787.s5.e1" text="tadalafil" /><pair ddi="false" e1="DDI-PubMed.31330787.s5.e0" e2="DDI-PubMed.31330787.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31330787.s5.e0" e2="DDI-PubMed.31330787.s5.e1" /></sentence><sentence text=" Blood samples were collected at predetermined time points after oral administration of tadalafil" /><sentence text=" As a result, systemic exposure of tadalafil in the ticagrelor-pretreated group was significantly increased compared to the non-pretreated group (1"><entity charOffset="35-44" id="DDI-PubMed.31330787.s7.e0" text="tadalafil" /><entity charOffset="52-62" id="DDI-PubMed.31330787.s7.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.31330787.s7.e0" e2="DDI-PubMed.31330787.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31330787.s7.e0" e2="DDI-PubMed.31330787.s7.e1" /></sentence><sentence text="61-fold), and the clearance of tadalafil in the ticagrelor-pretreated group was significantly reduced than the non-pretreated group (37%)"><entity charOffset="31-40" id="DDI-PubMed.31330787.s8.e0" text="tadalafil" /><entity charOffset="48-58" id="DDI-PubMed.31330787.s8.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.31330787.s8.e0" e2="DDI-PubMed.31330787.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31330787.s8.e0" e2="DDI-PubMed.31330787.s8.e1" /></sentence><sentence text=" The prediction of the drug profile through the one-compartment model could explain the differences of pharmacokinetic properties of tadalafil in the non-pretreated and ticagrelor-pretreated groups"><entity charOffset="133-142" id="DDI-PubMed.31330787.s9.e0" text="tadalafil" /></sentence><sentence text=" This study suggests that ticagrelor reduces a CYP3A-mediated tadalafil metabolism and that tadalafil and a combination regimen with tadalafil and ticagrelor requires dose control and specific pharmacotherapy"><entity charOffset="92-101" id="DDI-PubMed.31330787.s10.e0" text="tadalafil" /><entity charOffset="133-142" id="DDI-PubMed.31330787.s10.e1" text="tadalafil" /><entity charOffset="147-157" id="DDI-PubMed.31330787.s10.e2" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.31330787.s10.e0" e2="DDI-PubMed.31330787.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31330787.s10.e0" e2="DDI-PubMed.31330787.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31330787.s10.e0" e2="DDI-PubMed.31330787.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31330787.s10.e1" e2="DDI-PubMed.31330787.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31330787.s10.e1" e2="DDI-PubMed.31330787.s10.e2" /></sentence><sentence text="" /></document>